Retinal Capillary Hemangioblastoma: A Comprehensive Review on Treatments

Area of Science:

• Ophthalmology
• Oncology
• Genetics

Background:

• Retinal capillary hemangioblastoma (RCH) is a benign tumor often presenting as the initial symptom of von Hippel-Lindau (VHL) disease.
• RCH can lead to substantial vision impairment, underscoring the importance of timely diagnosis and intervention.

Purpose of the Study:

• To provide a comprehensive review of RCH, encompassing its epidemiology, pathophysiology, imaging, diagnosis, and treatment.
• To highlight recent advancements and their implications for clinical practice and patient management.

Main Methods:

• Review of current literature on RCH.
• Consolidation of information on diagnostic techniques and therapeutic strategies.
• Emphasis on novel approaches in imaging and treatment.

Main Results:

• Advanced imaging modalities like OCT and OCT angiography enhance diagnostic accuracy and monitoring.
• Established therapies (laser photocoagulation, cryotherapy, VEGF inhibitors) remain crucial.
• Emerging treatments (tyrosine kinase inhibitors, HIF inhibitors) show promise for refractory cases.
• Genetic testing aids in identifying VHL disease, facilitating early detection and management of systemic manifestations.

Conclusions:

• Integrated management of RCH, including genetic evaluation, is essential for VHL disease patients.
• New diagnostic and therapeutic strategies are improving the outlook for RCH.
• Prompt recognition and tailored treatment are key to preserving vision in RCH patients.